Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy

Molecular Therapy

Volumn 15, Issue 6, 2007, Pages 1121-1128

  Hamada, Katsuyuki ^a   Desaki, Junzo ^a   Nakagawa, Kou ^a   Zhang, Ting ^a   Shirakawa, Toshiro ^b   Gotoh, Akinobu ^c   Tagawa, Masatoshi ^d  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; INJECTION; MOUSE; NONHUMAN; OVARY CANCER; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HT29 CELLS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; REPLICATION COMPETENT VIRUSES;

EID: 34249287965     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300128     Document Type: Article

References (24)

1. Geoerger, B, Grill, J, Opolon, P, Morizet, J, Aubert, G, Terrier-Lacombe, MJ et al. (2002). Oncolytic activity of the El B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 62: 764-772.
2. Dematteo, RP, Yeh, H, Friscia, M, Caparrelli, D, Burke, C, Desai, N et al. (1999). Cellular immunity delimits adenoviral therapy strategies for the treatment of neoplastic diseases. Ann Surg Oncol 6: 88-94.
3. Mok, H, Palmer, DJ, Ng, P and Barry, MA (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce immune responses. Mol Ther 11: 66-79.
4. Steel, JC, Cavanagh, HM, Burton, MA and Kalle, WH (2004). Microsphereliposome complexes protect adenoviral vectors from neutralising antibody without losses in transfection efficiency in-vitro. J Pharm Pharmacol 56: 1371-1378.
5. Bouvet M, Fang, B, Ekmekcioglu, S, Ji, L, Bucana, CD, Hamada, K et al. (1998). Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 5: 189-195.
6. Jooss, K, Yang, Y and Wilson, JM (1996). Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 7: 1555-1566.
7. Ram, Z, Culver, KW, Oshiro, EM, Viola, JJ, DeVroom, HL, Otto, E et al. (1997). Therapy of malignant tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361.
8. Schwarzenberger, P, Harrison, L, Weinacker, A, Marrogi, A, Byme, P, Ramesh, R et al. (1998). The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study. Hum Gene Ther 9: 2641-2649.
9. Garcia-Castro, J, Martinez-Palacio, J, Lillo, R, Garcia-Sanchez, F, Alemany, R, Madero, L et al. (2005). Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 12: 341-349.
10. Coukos, G, Makrigiannakis, A, Kang, EH, Caparelli, D, Benjamin, I, Kaiser, LR et al. (1999). Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 5: 1523-1537.
11. Campbell, IG, Nicolai, HM, Foulkes, WD, Senger, G, Stamp, GW, Allan, G et al. (1994). A novel gene encoding a B-box protein Within the BRCA1 region at 17q21.1. Hum Mol Genet 3: 589-594.
12. Hamada, K, Kohno, S, Iwamoto, M, Yokota, H, Okada, M, Tagawa, M et al. (2003). Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 63: 2506-2512.
13. Miller, CG, Krummenacher, C, Eisenberg, RJ, Cohen, GH and Fraser, NW (2001). Development of a syngeneic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol Ther 3 160-168.
14. Sano, A, Maeda, M, Nagahara, S, Ochiya, T, Honma, K, Itoh, H et al. (2003). Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev 55: 1651-1677.
15. Cryole, MA, Chirmule, N, Zhang, Y and Wilson, JM (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13: 1887-1900.
16. Yotnda, P, Chen, DH, Chiu, W, Piedra, PA, Davis, A, Templeton, NS et al. (2002). Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5: 233-241.
17. Simamura, E, Hirai, KI, Shimada, H and Koyama, J (2001). Apoptosis and epithelial phagocytosis in mitomycin C-treated human pulmonary adenocarcinoma A549 cells. Tissue Cell 33: 161-168.
18. Roizman, B and Knipe DM (2001). Herpes simplex viruses and their replication. In: Knipe DM and Howley PM (eds). Fields Virology, 4th edn., Lippincott Williams and Wilkins: Philadelphia, PA. pp. 2399-2459.
19. Imler, JL, Chartier, C, Dreyer, D, Dieterle, A, Sainte-Marie, M, Faure, T et al. (1996). Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther 3: 75-84.
20. Qin, H and Chatterjee, SK (1996). Cancer gene therapy using tumor cells infected with recombinant vaccinia vinis expressing GM-CSF. Hum Gene Ther 7: 1853-1860.
21. Mahvi, DM, Sondel, PM, Yang, NS, Albertini, MR, Schiller, JH, Hank, J et al. (1997). Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 8: 875-891.
22. Shi, FS, Weber, S, Gan, J, Rakhmilevich, AL and Mahvi, DM (1999). Granulocytemacrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther 6: 81-88.
23. Armstrong, CA Botella, R, Galloway, TH, Murray, N, Kramp, JM, Song, IS et al. (1996). Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56: 2191-2198.
24. Mastrangelo, MJ, Maguire, HC Jr., Eisenlohr, LC, Laughlin, CE, Monken, CE, McCue, PA et al. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422.